Nemaura up on starting patient studies in health program with UK's NHS

Nemaura Medical

29/11/2022 19:35

** Shares of medical device maker Nemaura Medical Inc
 NMRD.O  rise 7.8% to $2.2
    ** Co commences patient studies of its proprietary metabolic
health program, Miboko, with the National Health Service (NHS)
in the United Kingdom
    ** The partnership with NHS is through medical centers that
partner with the NHS National Institute for Health and Care
Research (NIHR) to gather information 
    ** Miboko is a metabolic tracking program that integrates a
non-invasive glucose sensor with a lifestyle app based on diet,
exercise, and the user's individual glucose response to their
food intake 
    ** Miboko gives personalized recommendations to help reduce
weight, avoid serious health issues, such as heart disease and
diabetes - Co 
    ** NMRD says Mibiko complements its diabetes program that is
being commercialized for people with type 2 diabetes in the U.S.
through strategic alliances 
    ** Including session's gain, stock down 51.5% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))